Onset and reversibility of changes in secretory function and composition of isolated rat pancreatic islets following long-term administration of high or low tolbutamide doses

Abstract

Chronic administration of a high tolbutamide dose to rats induces islet hypertrophy associated with a decreased insulin content per islet and with a diminished insulin release in response to a glucose or leucine stimulus. These changes are reversible after discontinuation of tolbutamide. Chronic administration of a low tolbutamide dose (effective dose 30%) has no effect on islet size, on insulin content per islet, or on leucine-induced insulin release. In contrast, the glucose-induced insulin release is impaired. However, glucose-induced insulin release is normal in the presence of glucagon (5 μg/ml) or theophylline (5 m M). Since islet hypertrophy occurs following admin-istration of high tolbutamide doses only and is associated with hypofunction rather than with hyperfunction, it seems hardly conceivable that the therapeutic principle of tolbutamide is based on a beta-cytotrophic effect. B-cell hypofunction seems to be due to at least three factors: the decrease in the insulin content per islet, an impairment in secretory signal recognition, and an interference with the process of signal transmission.